Phase 3 Readout
FATE: Phase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety
June 21, 2026 · rph-002. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 21, 2026
- Company
- FATE THERAPEUTICS INC (FATE)
- Drug
- rph-002
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety
- Company
- FATE THERAPEUTICS INC (FATE)
- Drug
- rph-002
- Indication
- Head and Neck Squamous Cell Carcinoma